Abstract
Current vaccine research is now heavily focused on improving the efficacy and potency of sub-unit peptide vaccines. Many successful vaccines developed in past decades have been able to sufficiently prime proper immune responses without the use of any specific adjuvant immune mediators. Due to the intrinsic nature of more immune-evading pathogens and neoplasms, novel “tricks” are needed to elucidate a proper and protective immune response. It is important to note that without cytokines, proper execution of the immune response would be completely inhibited. They are responsible for the recruitment and chemo-tactic movement of most innate cellular effectors such as polymorphonucleocytes (PMN), macrophages, and dendritic cells. Most importantly, the entire Th1/Th2 balance is completely dependent on the unique nature and signature of differential cytokine production. These expression signatures are crucially needed to tip the scale either way, depending on which immune reaction is appropriate. This review will specifically explain the use of Th1 inducing cytokines as an adjuvant in current vaccine development. This rapidly developing field aims to produce more powerful and effective Th1 responses in the hopes of improving the treatment of cancer, intracellular infectious agents, and autoimmune diseases.
Keywords: Vaccines, sub-unit vaccines, peptides, cytokines, adjuvants, Th1/Th2 responses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Volume: 8 Issue: 4
Author(s): Sebastian Di Cesare, Daniel Abourbih, Rubens N. Belfort, Luca A. Petruccelli and Miguel N. Burnier Jr.
Affiliation:
Keywords: Vaccines, sub-unit vaccines, peptides, cytokines, adjuvants, Th1/Th2 responses
Abstract: Current vaccine research is now heavily focused on improving the efficacy and potency of sub-unit peptide vaccines. Many successful vaccines developed in past decades have been able to sufficiently prime proper immune responses without the use of any specific adjuvant immune mediators. Due to the intrinsic nature of more immune-evading pathogens and neoplasms, novel “tricks” are needed to elucidate a proper and protective immune response. It is important to note that without cytokines, proper execution of the immune response would be completely inhibited. They are responsible for the recruitment and chemo-tactic movement of most innate cellular effectors such as polymorphonucleocytes (PMN), macrophages, and dendritic cells. Most importantly, the entire Th1/Th2 balance is completely dependent on the unique nature and signature of differential cytokine production. These expression signatures are crucially needed to tip the scale either way, depending on which immune reaction is appropriate. This review will specifically explain the use of Th1 inducing cytokines as an adjuvant in current vaccine development. This rapidly developing field aims to produce more powerful and effective Th1 responses in the hopes of improving the treatment of cancer, intracellular infectious agents, and autoimmune diseases.
Export Options
About this article
Cite this article as:
Di Cesare Sebastian, Abourbih Daniel, Belfort N. Rubens, Petruccelli A. Luca and Burnier Jr. N. Miguel, Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (4) . https://dx.doi.org/10.2174/187152309789839046
DOI https://dx.doi.org/10.2174/187152309789839046 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimers Disease: Cathepsin Inhibitors as Potential Therapeutics
CNS & Neurological Disorders - Drug Targets The Role of Mitochondria in Systemic Lupus Erythematosus: A Glimpse of Various Pathogenetic Mechanisms
Current Medicinal Chemistry Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Current Drug Targets Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design The Role of Autophagy in Rheumatic Disease
Current Drug Targets Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Contribution of the Rho-kinase to Systemic Sclerosis and Behçet’s Disease
Current Pharmaceutical Design Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Current Drug Metabolism Animal Models to Investigate Pathomechanisms and Evaluate Novel Treatments for Autoimmune Bullous Dermatoses
Current Pharmaceutical Design Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry